As the search for new and better treatments for Alzheimer’s disease continues, a phase 1 proof-of-concept study evaluating senolytic therapy breaks new ground.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Longo, F. M. & Massa, S. M. J. Prev. Alzheimers Dis. 7, 138–139 (2020).
Orr, M. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02543-w (2023).
Guerrero, A., De Strooper, B. & Arancibia-Carcamo, I. L. Trends Neurosc.i 44, 714–727 (2021).
Behfar, Q., Ramirez Zuniga, A. & Martino-Adami, P. V. J. Prev. Alzheimers Dis. 9, 523–531 (2022).
Lee, H. J., Yoon, Y. S. & Lee, S. J. J. Mol. Biol. 435, 168114 (2023).
Musi, N. et al. Aging Cell 17, e12840 (2018).
Zhang, P. et al. Nat. Neurosci. 22, 719–728 (2019).
Gaikwad, S. et al. Cell Rep. 36, 109419 (2021).
Li, Y., Lu, J., Hou, Y., Huang, S. & Pei, G. Front. Cell Neurosci. 16, 906270 (2022).
Nambiar, A. et al. EBioMedicine 90, 104481 (2023).
Hickson, L. J. et al. EBioMedicine 47, 446–456 (2019).
Hickson, L. J. et al. EBioMedicine 52, 102595 (2020).
F.M.L. and S.M.M. are listed as inventors on patents relating to small molecule, therapeutic approaches for Alzheimer’s and other neurodegenerative diseases and are entitled to royalties. F.M.L. is a principal of, and has a financial interest in PharmatrophiX, a company that has licensed several of these patents.
About this article
Cite this article
Longo, F.M., Massa, S.M. Senolytic therapy for Alzheimer’s disease. Nat Med 29, 2409–2411 (2023). https://doi.org/10.1038/s41591-023-02541-y